- Home
- UBSI vs GKOS Comparison
UBSI vs GKOS Comparison
Compare UBSI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- GKOS
- Stock Information
- Founded
- UBSI 1982
- GKOS 1998
- Country
- UBSI United States
- GKOS United States
- Employees
- UBSI N/A
- GKOS N/A
- Industry
- UBSI Major Banks
- GKOS Medical/Dental Instruments
- Sector
- UBSI Finance
- GKOS Health Care
- Exchange
- UBSI Nasdaq
- GKOS Nasdaq
- Market Cap
- UBSI 5.3B
- GKOS 5.8B
- IPO Year
- UBSI N/A
- GKOS 2015
- Fundamental
- Price
- UBSI $38.41
- GKOS $103.50
- Analyst Decision
- UBSI Hold
- GKOS Strong Buy
- Analyst Count
- UBSI 4
- GKOS 13
- Target Price
- UBSI $40.13
- GKOS $135.15
- AVG Volume (30 Days)
- UBSI 905.9K
- GKOS 903.0K
- Earning Date
- UBSI 07-24-2025
- GKOS 07-30-2025
- Dividend Yield
- UBSI 3.85%
- GKOS N/A
- EPS Growth
- UBSI 2.88
- GKOS N/A
- EPS
- UBSI 2.70
- GKOS N/A
- Revenue
- UBSI $1,021,155,000.00
- GKOS $404,523,000.00
- Revenue This Year
- UBSI $20.44
- GKOS $27.88
- Revenue Next Year
- UBSI $5.18
- GKOS $27.60
- P/E Ratio
- UBSI $14.25
- GKOS N/A
- Revenue Growth
- UBSI 0.82
- GKOS 23.92
- 52 Week Low
- UBSI $30.51
- GKOS $77.10
- 52 Week High
- UBSI $44.43
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- UBSI 65.26
- GKOS 61.38
- Support Level
- UBSI $36.27
- GKOS $100.92
- Resistance Level
- UBSI $36.88
- GKOS $106.52
- Average True Range (ATR)
- UBSI 0.70
- GKOS 3.30
- MACD
- UBSI 0.22
- GKOS 0.37
- Stochastic Oscillator
- UBSI 99.33
- GKOS 71.27
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.